The estimated Net Worth of Leslie Tari is at least $3.08 Million dollars as of 11 March 2024. Leslie Tari owns over 21,029 units of Cidara Therapeutics Inc stock worth over $3,005,873 and over the last 3 years Leslie sold CDTX stock worth over $69,730.
Leslie has made over 7 trades of the Cidara Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Leslie sold 21,029 units of CDTX stock worth $14,089 on 11 March 2024.
The largest trade Leslie's ever made was selling 21,029 units of Cidara Therapeutics Inc stock on 11 March 2024 worth over $14,089. On average, Leslie trades about 7,428 units every 67 days since 2021. As of 11 March 2024 Leslie still owns at least 258,681 units of Cidara Therapeutics Inc stock.
You can see the complete history of Leslie Tari stock trades at the bottom of the page.
Leslie's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio..., and Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include: